A Study to Evaluate the Efficacy and Safety of Gefitinib as First-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations

Trial Profile

A Study to Evaluate the Efficacy and Safety of Gefitinib as First-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BE-Positive
  • Most Recent Events

    • 15 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top